Two small companies have today announced initial clinical trials of two new investigational agents for the treatment of prostate cancer.
Bostwick Therapeutics (a division of Bostwick Laboratories) has just announced that it has received clearance to initiate the CRITICAL (CRyotherapy and IntraTumoral Immunotherapy with immature dendritic Cells (AutoLogous)) trial, a clinical trial examining the potential of a novel combination of cryoablation and intra-tumoral injection of “virgin” dendritic cells (VDC2008) to treat men with metastatic androgen-independent prostate cancer.
In addition, Progenics Pharmaceuticals has announced the initiation of a phase I dose-escalation clinical study of its prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC). PSMA ADC is an investigational therapy that combines a prostate-cancer antibody with a derivative of a cancer drug known as auristatin.
Filed under: Drugs in development, Management, Treatment | Tagged: auristatin, Bostwick Therapeutics, dendritic cells, Progenics, PSMA, VDC2008 |
Leave a Reply